Granted Patent
B2
US 12,194,321 · App. 16/972,469 · Granted Jan 14, 2025
Camptothecin conjugates
Assignee:
Seagen Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Antibody conjugates with camptothecin compounds are described, with methods of use and preparations.
Claims (103)
1. A Camptothecin Conjugate having the formula:
L-(Q-D) p
or a salt thereof, wherein
L is a Ligand Unit, wherein the Ligand Unit is an antibody that selectively binds to a cancer cell antigen or antigen-binding fragment thereof;
subscript p is an integer ranging from 1 to 16;
-Q-D is
wherein
the wavy line indicates the site of covalent attachment to L;
Z is a Stretcher Unit, wherein Z is
wherein:
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to A;
the wavy line marked with a triple asterisk (***) indicates the point of covalent attachment to a sulfur atom of L; and
R 17 is —C 1 -C 10 alkylene-C(═O)—, optionally substituted by —(CH 2 ) x NH 2 , wherein x is an integer from 1 to 4; and
A is a bond or a Connector Unit having the formula:
wherein
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to Z;
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of Q-D;
R 100 and R 111 are each independently hydrogen or —C 1 -C 3 alkyl; and
c is an integer from 1 to 5.
2. The Camptothecin Conjugate of claim 1 , or a salt thereof, wherein R 17 is —(CH 2 ) 2-5 —C(═O)—.
3. The Camptothecin Conjugate of claim 1 , or a salt thereof, wherein Z is
optionally having the succinimide ring in hydrolyzed form as a succinic acid amide moiety, wherein the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to A; and the wavy line marked with a triple asterisk (***) indicates the point of covalent attachment to a sulfur atom of L.
4. The Camptothecin Conjugate of claim 3 , or a salt thereof, wherein Z is
5. The Camptothecin Conjugate of claim 3 , or a salt thereof, wherein Z is
6. The Camptothecin Conjugate of claim 3 , or a salt thereof, wherein Z is
7. The Camptothecin Conjugate of claim 1 , or a salt thereof, wherein A is a Connector Unit.
8. The Camptothecin Conjugate of claim 1 , or a salt thereof, wherein A has the formula:
wherein
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of Q-D; and
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to Z.
9. The Camptothecin Conjugate of claim 1 , or a salt thereof, wherein —Z-A- has the formula:
wherein
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of Q-D; and
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to L.
10. The Camptothecin Conjugate of claim 1 , or a salt thereof, having the formula of:
wherein
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to Z.
11. A Camptothecin Conjugate having the formula:
L-(Q-D) p
or a salt thereof, wherein
L is a Ligand Unit, wherein the Ligand Unit is an antibody that selectively binds to a cancer cell antigen or antigen-binding fragment thereof;
subscript p is an integer ranging from 1 to 16; and
wherein Q-D has the formula:
wherein
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to L.
12. A Camptothecin Conjugate having the formula:
L-(Q-D) p
or a salt thereof, wherein
L is a Ligand Unit, wherein the Ligand Unit is an antibody that selectively binds to a cancer cell antigen or antigen-binding fragment thereof;
subscript p is an integer ranging from 1 to 16; and
wherein -Q-D has the formula:
wherein
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to L.
13. A Camptothecin-Linker compound, or a salt thereof, having the structure of:
wherein
Z′ is a Stretcher Unit precursor, wherein Z′ is
wherein:
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to A;
R 17 is —C 1 -C 10 alkylene-C(═O)—, optionally substituted by —(CH 2 ) x NH 2 , wherein x is an integer from 1 to 4;
A is a bond or a Connector Unit having the formula:
wherein
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to Z′;
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of the Camptothecin-Linker structure;
R 100 and R 111 are each independently hydrogen or —C 1 -C 3 alkyl; and
c is an integer from 1 to 5.
14. The Camptothecin-Linker compound of claim 13 , or a salt thereof, wherein R 17 is —(CH 2 ) 2-5 —C(═O)—.
15. The Camptothecin-Linker compound of claim 13 , or a salt thereof, wherein Z′ is
wherein the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to A.
16. The Camptothecin-Linker compound of claim 13 , or a salt thereof, wherein A is a Connector Unit.
17. The Camptothecin-Linker compound of claim 13 , or a salt thereof, wherein A has the formula:
wherein
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of the Camptothecin-Linker structure; and
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to Z′.
18. The Camptothecin-Linker compound of claim 13 , or a salt thereof, wherein Z′-A- has the formula:
wherein
the wavy line marked with a double asterisk (**) indicates the site of covalent attachment to the remainder of the Camptothecin-Linker structure.
19. The Camptothecin-Linker compound of claim 13 , or a salt thereof, having the formula of:
wherein
the wavy line marked with a single asterisk (*) indicates the point of covalent attachment to Z′.
20. A Camptothecin-Linker compound, or a salt thereof, having the formula:
21. A pharmaceutically acceptable composition comprising a Camptothecin Conjugate of claim 1 , or a salt thereof, and at least one pharmaceutically acceptable excipient.
22. A pharmaceutically acceptable composition comprising a Camptothecin Conjugate of claim 11 , or a salt thereof, and at least one pharmaceutically acceptable excipient.
23. A pharmaceutically acceptable composition comprising a Camptothecin Conjugate of claim 12 , or a salt thereof, and at least one pharmaceutically acceptable excipient.
24. A method of treating cancer in a subject in need thereof comprising administering to the subject an effective amount of a Camptothecin Conjugate of claim 1 , or a salt thereof.
25. A method of treating cancer in a subject in need thereof comprising administering to the subject an effective amount of a Camptothecin Conjugate of claim 11 , or a salt thereof.
26. A method of treating cancer in a subject in need thereof comprising administering to the subject an effective amount of a Camptothecin Conjugate of claim 12 , or a salt thereof.
27. The method of claim 24 , wherein the cancer is selected from the group consisting of lymphomas, leukemias, and solid tumors.
28. The method of claim 27 , wherein the cancer is a lymphoma or a leukemia.
29. The method of claim 25 , wherein the cancer is selected from the group consisting of lymphomas, leukemias, and solid tumors.
30. The method of claim 29 , wherein the cancer is a lymphoma or a leukemia.
31. The method of claim 26 , wherein the cancer is selected from the group consisting of lymphomas, leukemias, and solid tumors.
32. The method of claim 31 , wherein the cancer is a lymphoma or a leukemia.
33. A method of preparing a Camptothecin Conjugate of claim 1 , or a salt thereof, said method comprising the step of contacting an antibody or antigen-binding fragment thereof having a functional group reactive towards Z′ of a Camptothecin-Linker Compound of claim 13 , or a salt thereof, thereby forming a covalent bond between the Ligand Unit and Stretcher Unit (Z) of the Camptothecin Conjugate, which corresponds in structure to the antibody or antigen-binding fragment thereof and Z′, respectively.
34. The method of claim 33 , wherein the antibody or antigen-binding fragment thereof is an antibody having at least one cysteine residue in which the reactive functional group is thiol.
35. The Camptothecin Conjugate of claim 1 , wherein L is an antibody that specifically binds to an antigen selected from the group consisting of CD19, CD30, CD33, CD70, and LIV-1.
36. The Camptothecin Conjugate of claim 1 , wherein L is an antibody that specifically binds to an antigen of CD30.
37. The Camptothecin Conjugate of claim 36 , wherein the antibody is cAC10.
38. The Camptothecin Conjugate of claim 11 , wherein L is an antibody that specifically binds to an antigen selected from the group consisting of CD19, CD30, CD33, CD70, and LIV-1.
39. The Camptothecin Conjugate of claim 11 , wherein L is an antibody that specifically binds to an antigen of CD30.
40. The Camptothecin Conjugate 103, wherein the antibody is cAC10.
41. The Camptothecin Conjugate of claim 12 , wherein L is an antibody that specifically binds to an antigen selected from the group consisting of CD19, CD30, CD33, CD70, and LIV-1.
42. The Camptothecin Conjugate of claim 12 , wherein L is an antibody that specifically binds to an antigen of CD30.
43. The Camptothecin Conjugate of claim 42 , wherein the antibody is cAC10.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 11, 2024
From: JEFFREY, SCOTT; LYSKI, RYAN; LAU, ULAND
To: SEATTLE GENETICS, INC.
Reel/Frame 069202/0136 →
CHANGE OF NAME
Recorded Nov 11, 2024
From: SEATTLE GENETICS, INC.
To: SEAGEN INC.
Reel/Frame 069325/0677 →
Continuity (3)
Provisional Application
62777491
· Dec 10, 2018
Provisional Application
62681847
· Jun 7, 2018
References Cited (400)
US 4179337A
· Davis
· 1979
[cited by applicant]
US 4301144A
· Iwashita
· 1981
[cited by applicant]
US 4474893A
· Reading
· 1984
[cited by applicant]
US 4496689A
· Mitra
· 1985
[cited by applicant]
US 4640835A
· Shimizu
· 1987
[cited by applicant]
US 4670417A
· Iwasaki
· 1987
[cited by applicant]
US 4676980A
· Segal
· 1987
[cited by applicant]
US 4714681A
· Reading
· 1987
[cited by applicant]
US 4751180A
· Cousens et al.
· 1988
[cited by applicant]
US 4791192A
· Nakagawa
· 1988
[cited by applicant]
US 4816397A
· Boss
· 1989
[cited by applicant]
US 4816567A
· Cabilly
· 1989
[cited by applicant]
US 4925648A
· Hansen
· 1990
[cited by applicant]
US 4935233A
· Bell et al.
· 1990
[cited by applicant]
US 5225539A
· Winter
· 1993
[cited by applicant]
US 5342947A
· Lackey et al.
· 1994
[cited by applicant]
US 5364858A
· Wall et al.
· 1994
[cited by applicant]
US 5496630A
· Hawrylko et al.
· 1996
[cited by applicant]
US 5496830A
· Shapiro
· 1996
[cited by applicant]
US 5500362A
· Robinson
· 1996
[cited by applicant]
US 5530101A
· Queen
· 1996
[cited by applicant]
US 5559235A
· Luzzio et al.
· 1996
[cited by applicant]
US 5573920A
· Randle
· 1996
[cited by applicant]
US 5585089A
· Queen
· 1996
[cited by applicant]
US 5601819A
· Wong
· 1997
[cited by applicant]
US 5624821A
· Winter
· 1997
[cited by applicant]
US 5672662A
· Harris
· 1997
[cited by applicant]
US 5731168A
· Carter
· 1998
[cited by applicant]
US 5757078A
· Matsuda
· 1998
[cited by applicant]
US 5821337A
· Carter
· 1998
[cited by applicant]
US 5834597A
· Tso
· 1998
[cited by applicant]
US 5859205A
· Adair
· 1999
[cited by applicant]
US 6077939A
· Wei
· 2000
[cited by applicant]
US 6194551B1
· Idusogie
· 2001
[cited by applicant]
US 6407213B1
· Carter
· 2002
[cited by applicant]
US 6602684B1
· Umana
· 2003
[cited by applicant]
US 6624821B1
· Shin et al.
· 2003
[cited by applicant]
US 6629995B1
· Wrenn, Jr. et al.
· 2003
[cited by applicant]
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 6881557B2
· Foote
· 2005
[cited by applicant]
US 6982321B2
· Winter
· 2006
[cited by applicant]
US 7087409B2
· Barbas, III
· 2006
[cited by applicant]
US 7090843B1
· Francisco et al.
· 2006
[cited by applicant]
US 7332581B2
· Presta
· 2008
[cited by applicant]
US 7361740B2
· Hinton et al.
· 2008
[cited by applicant]
US 7371826B2
· Presta
· 2008
[cited by applicant]
US 7521541B2
· Eigenbrot
· 2009
[cited by applicant]
US 7527791B2
· Adams
· 2009
[cited by applicant]
US 7659241B2
· Senter
· 2010
[cited by applicant]
US 7745394B2
· Doronina
· 2010
[cited by applicant]
US 7829531B2
· Senter
· 2010
[cited by applicant]
US 7851437B2
· Senter
· 2010
[cited by applicant]
US 7923538B2
· Shitara
· 2011
[cited by applicant]
US 7964566B2
· Doronina
· 2011
[cited by applicant]
US 7968687B2
· Mcdonagh
· 2011
[cited by applicant]
US 7994290B2
· Shitara
· 2011
[cited by applicant]
US 8038273B2
· Frasure et al.
· 2011
[cited by applicant]
US 8263083B2
· Oflazoglu
· 2012
[cited by applicant]
US 8288352B2
· Doronina
· 2012
[cited by applicant]
US 8293714B2
· Doppalapudi et al.
· 2012
[cited by applicant]
US 8470329B2
· Oflazoglu
· 2013
[cited by applicant]
US 8512707B2
· Doronina
· 2013
[cited by applicant]
US 8906376B2
· Senter
· 2014
[cited by applicant]
US 8968742B2
· Morrison
· 2015
[cited by applicant]
US 9211319B2
· Sievers
· 2015
[cited by applicant]
US 9314538B2
· Satpayev
· 2016
[cited by applicant]
US 9504756B2
· Lyon
· 2016
[cited by applicant]
US 9713648B2
· Sievers
· 2017
[cited by applicant]
US 9926376B2
· Morrison
· 2018
[cited by applicant]
US 9962454B2
· Satpayev
· 2018
[cited by applicant]
US 9987374B2
· Li
· 2018
[cited by applicant]
US RE47103E
· An et al.
· 2018
[cited by applicant]
US 20020161231A1
· Kawaguchi et al.
· 2002
[cited by applicant]
US 20020164328A1
· Shinkawa
· 2002
[cited by applicant]
US 20030115614A1
· Kanda
· 2003
[cited by applicant]
US 20030157108A1
· Presta
· 2003
[cited by applicant]
US 20040093621A1
· Shitara
· 2004
[cited by applicant]
US 20040109865A1
· Niwa
· 2004
[cited by applicant]
US 20040110282A1
· Kanda
· 2004
[cited by applicant]
US 20040110704A1
· Yamane
· 2004
[cited by applicant]
US 20040132140A1
· Satoh
· 2004
[cited by applicant]
US 20050123546A1
· Umana
· 2005
[cited by applicant]
US 20050256030A1
· Feng
· 2005
[cited by applicant]
US 20140099256A1
· Zheng et al.
· 2014
[cited by applicant]
US 20140099258A1
· Govindan
· 2014
[cited by applicant]
US 20140107342A1
· Zhou et al.
· 2014
[cited by applicant]
US 20150037340A1
· Beau-larvor
· 2015
[cited by applicant]
US 20160106861A1
· Beau-larvor
· 2016
[cited by applicant]
US 20170182179A1
· Ackler
· 2017
[cited by applicant]
US 20190343828A1
· Jeffrey
· 2019
[cited by applicant]
US 20200102399A1
· Manley et al.
· 2020
[cited by applicant]
US 20200239585A1
· Heiser
· 2020
[cited by applicant]
US 20200247902A1
· Prendergast
· 2020
[cited by applicant]
US 20200283540A1
· Kennedy
· 2020
[cited by applicant]
US 20200347149A1
· Doronina
· 2020
[cited by applicant]
US 20210138077A1
· Bindman et al.
· 2021
[cited by applicant]
US 20220193069A1
· Jeffrey et al.
· 2022
[cited by applicant]
US 20230087871A1
· Nicolazzi
· 2023
[cited by applicant]
US 20230149557A1
· Nicolazzi
· 2023
[cited by applicant]
US 20230151088A1
· Nicolazzi
· 2023
[cited by applicant]
US 20230181755A1
· Nicolazzi
· 2023
[cited by applicant]
US 20230190949A1
· Ryan et al.
· 2023
[cited by applicant]
US 20230381321A1
· Lyski
· 2023
[cited by examiner]
US 20240076394A1
· Heiser et al.
· 2024
[cited by applicant]
US 20240207427A1
· Jeffrey
· 2024
[cited by applicant]
US 20240226313A1
· Baudat
· 2024
[cited by applicant]
CA 2087898A1
· 1993
[cited by applicant]
EP 0171496A2
· 1986
[cited by applicant]
EP 0173494A2
· 1986
[cited by applicant]
EP 0184187A2
· 1986
[cited by applicant]
EP 0401384A1
· 1990
[cited by applicant]
EP 0540099A1
· 1993
[cited by applicant]
EP 0556585A2
· 1993
[cited by applicant]
EP 0629240A1
· 1994
[cited by applicant]
EP 0845464A2
· 1998
[cited by applicant]
WO 198601533A1
· 1986
[cited by applicant]
WO 198702671A1
· 1987
[cited by applicant]
WO 199012874A2
· 1990
[cited by applicant]
WO 199012874A3
· 1991
[cited by applicant]
WO 1991000360A1
· 1991
[cited by applicant]
WO 199205793A1
· 1992
[cited by applicant]
WO 199208802A1
· 1992
[cited by applicant]
WO 199222653A1
· 1992
[cited by applicant]
WO 199308829A1
· 1993
[cited by applicant]
WO 199317105A1
· 1993
[cited by applicant]
WO 199317715A1
· 1993
[cited by applicant]
WO 199410308A1
· 1994
[cited by applicant]
WO 199730087A1
· 1997
[cited by applicant]
WO 199734631A1
· 1997
[cited by applicant]
WO 199858964A1
· 1998
[cited by applicant]
WO 199922764A1
· 1999
[cited by applicant]
WO 199951642A1
· 1999
[cited by applicant]
WO 200061739A1
· 2000
[cited by applicant]
WO 200069459A1
· 2000
[cited by applicant]
WO 2001029246A1
· 2001
[cited by applicant]
WO 200174402A2
· 2001
[cited by applicant]
WO 2002031140A1
· 2002
[cited by applicant]
WO 200240040A1
· 2002
[cited by applicant]
WO 200243661A2
· 2002
[cited by applicant]
WO 200243661A3
· 2003
[cited by applicant]
WO 2003011878A2
· 2003
[cited by applicant]
WO 200174402A3
· 2003
[cited by applicant]
WO 2003084570A1
· 2003
[cited by applicant]
WO 2003085107A1
· 2003
[cited by applicant]
WO 2003085119A1
· 2003
[cited by applicant]
WO 2004056312A2
· 2004
[cited by applicant]
WO 200492219A2
· 2004
[cited by applicant]
WO 2005035586A1
· 2005
[cited by applicant]
WO 2005035778A1
· 2005
[cited by applicant]
WO 2005053742A1
· 2005
[cited by applicant]
WO 2006006196A2
· 2006
[cited by applicant]
WO 2006036291A2
· 2006
[cited by applicant]
WO 2006006196A3
· 2006
[cited by applicant]
WO 2006113909A2
· 2006
[cited by applicant]
WO 2007005643A2
· 2007
[cited by applicant]
WO 2007005644A2
· 2007
[cited by applicant]
WO 2007016361A2
· 2007
[cited by applicant]
WO 2007016431A2
· 2007
[cited by applicant]
WO 2007005643A3
· 2007
[cited by applicant]
WO 2007044616A2
· 2007
[cited by applicant]
WO 2007005644A3
· 2007
[cited by applicant]
WO 2007016431A3
· 2007
[cited by applicant]
WO 2007044616A3
· 2007
[cited by applicant]
WO 2007112193A2
· 2007
[cited by applicant]
WO 2007016361A3
· 2007
[cited by applicant]
WO 2006113909A3
· 2008
[cited by applicant]
WO 2008077546A1
· 2008
[cited by applicant]
WO 2007112193A3
· 2008
[cited by applicant]
WO 2009048967A1
· 2009
[cited by applicant]
WO 2009089004A1
· 2009
[cited by applicant]
WO 2013000269A1
· 2013
[cited by applicant]
WO 2013173337A2
· 2013
[cited by applicant]
WO 2014079886A1
· 2014
[cited by applicant]
WO 2015057699A2
· 2015
[cited by applicant]
WO 2013173337A3
· 2015
[cited by applicant]
WO 2015095755A1
· 2015
[cited by applicant]
WO 2015057699A3
· 2015
[cited by applicant]
WO 2015155998A1
· 2015
[cited by applicant]
WO 2016094517A1
· 2016
[cited by applicant]
WO 2016149535A1
· 2016
[cited by applicant]
WO 2017004330A1
· 2017
[cited by applicant]
WO 2017165851A1
· 2017
[cited by applicant]
WO 2017210473A1
· 2017
[cited by applicant]
WO 2018112253A1
· 2018
[cited by applicant]
WO 2019075188A1
· 2019
[cited by applicant]
WO 2019089870A1
· 2019
[cited by applicant]
WO 2019195665A1
· 2019
[cited by applicant]
WO 2019236954A1
· 2019
[cited by applicant]
WO 2020161214A1
· 2020
[cited by applicant]
WO 2021055865A1
· 2021
[cited by applicant]
WO 2021067820A1
· 2021
[cited by applicant]
WO 2021067861A1
· 2021
[cited by applicant]
WO 2021214221A1
· 2021
[cited by applicant]
WO 2021214222A1
· 2021
[cited by applicant]
WO 2021214223A1
· 2021
[cited by applicant]
WO 2021214227A1
· 2021
[cited by applicant]
WO 2021231568A1
· 2021
[cited by applicant]
WO 2022048883A1
· 2022
[cited by applicant]
WO 2022101165A1
· 2022
[cited by applicant]
WO 2022120084A1
· 2022
[cited by applicant]
WO 2022198231A1
· 2022
[cited by applicant]
WO 2022198232A1
· 2022
[cited by applicant]
WO 2023079057A1
· 2023
[cited by applicant]
WO 2023099683A1
· 2023
[cited by applicant]
U.S. Appl. No. 18/496,756, filed Oct. 27, 2023, Seagen Inc.
[cited by examiner]
U.S. Appl. No. 18/511,818, filed Nov. 16, 2023, Seagen Inc.
[cited by examiner]
Arimondo, P. B. et al. J. Biol. Chem. 2002. 277(5):3132-40. (Year: 2002).
[cited by examiner]
Xie, Z., et al., Bioorg. Med. Chem. Lett., vol. 5, No. 19, pp. 2189-2194. (Year: 1995).
[cited by examiner]
Amsberry, K.L. et al. (1990) “The Lactonizatin of 2′-Hydroxyhydrocinnamic Acid Amides: A Potential Prodrug for Amines,” J. Org. Chem. 55(23):5867-5877.
[cited by applicant]
Bacillieri, M. et al. (2011). “A Novel Generalized 3D-QSAR Model of Camptothecin Analogs,” Molecular Informatics 30:927-938.
[cited by applicant]
Beidler, C.B. et al. (Dec. 1, 1988). “Cloning and High Level Expression of a Chimeric Antibody With Specificity for Human Carcinoembryonic Antigen,” J. Immunol. 141(11):4053-4060.
[cited by applicant]
Better, M. et al. (May 20, 1988). “
[cited by applicant]
Burke, P.J. et al. (Jun. 2009). “Design, Synthesis, and Biological Evaluation of Antibody-Drug Conjugates Comprised of Potent Camptothecin Analogues,” Bioconj. Chem. 20(6):1242-1250.
[cited by applicant]
Chandregowda, V. et al. (2007, e-pub. Nov. 17, 2006). “One-Pot Conversion of 2-nitrobenzonitriles to Quinazolin-4 (3H)-Ones and Synthesis of Gefitinib and Erlotinib Hydrochloride,” Heterocycles 71(1):39-48.
[cited by applicant]
Dong, W. et al. (Apr. 1, 2019, e-pub. Feb. 7, 2019). “Antibody-Drug Conjugates of 7-ethyl-10-hydroxycamptothecin: Sacituzumab govitecan and labetuzumab govitecan,” European Journal of Medicinal Chemistry (2019) 167:583-…
[cited by applicant]
Final Office Action, mailed May 27, 2021, for U.S. Appl. No. 16/376,302, filed Apr. 5, 2019, 20 pages.
[cited by applicant]
Foster, A.B. (1985). “Deuterium Isotope Effects in the Metabolism of Drugs and Xenobiotics: Implications for Drug Design,” Adv. Drug Res. 14:1-40, 43 pages.
[cited by applicant]
Gaertner, H.F. et al. (Mar. 11, 1994). “Chemo-Enzymic Backbone Engineering of Proteins,” J. Biol. Chem. 269(10):7224-7230.
[cited by applicant]
Gillette, J.R. et al. (Mar. 15, 1994). “Theory for the Observed Isotope Effects on the Formation of Multiple Products by Different Kinetic Mechanisms of Cytochrome P450 Enzymes,” Biochemistry 33(10):2927-2937.
[cited by applicant]
Goodson, R.J. et al. (Apr. 1990). “Site-Directed Pegylation of Recombinatnt Interleukin-2 at Its Glycosylation Site,” Bio/Technology 8:343-346.
[cited by applicant]
Hansch, C. et al. (2007). “20-(S)-Camptothecin Analogues as DNA Topoisomerase I Inhibitors: A QSAR Study,” ChemMedChem 2:1807-1813.
[cited by applicant]
Hanzlik, R. et al. (1990). “Active Site Dynamics of Toluene Hydroxylation by Cytochrome P-4501,” J. Org. Chem.; 55(13):3992-3997.
[cited by applicant]
Hay, M.P. et al. (Aug. 2, 1999). “A 2-nitroimidazole Carbamate Prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1,2-dihydro-3H-benz[e]indole (amino-seco-CBI-TMI) for Use With ADEPT and GDEPT,…
[cited by applicant]
International Preliminary Report on Patentability, issued Dec. 8, 2020, for PCT Application No. PCT/US2019/035971, filed Jun. 7, 2019, 11 pages.
[cited by applicant]
International Preliminary Report on Patentability, issued Oct. 6, 2020, for PCT Application No. PCT/US2019/025968, filed Apr. 5, 2019, 7 pages.
[cited by applicant]
International Search Report and Written Opinion, dated Aug. 19, 2019, for PCT Application No. PCT/US2019/025968, filed Apr. 5, 2019, 15 pages.
[cited by applicant]
International Search Report and Written Opinion, dated Jan. 15, 2021, for PCT Application No. PCT/US2020/054087, filed Oct. 2, 2020, 15 pages.
[cited by applicant]
International Search Report and Written Opinion, dated Sep. 20, 2019, for PCT Application No. PCT/US2019/035971, filed Jun. 7, 2019, 18 pages.
[cited by applicant]
Jarman, M. (1995) “The Deuterium Isotope Effect for the α-hydroxylation of Tamoxifen by Rat Liver Microsomes Accounts for the Reduced Genotoxicity of [D5-ethyl]tamoxifen,” Carcinogenesis, 16(4):683-688.
[cited by applicant]
Jeffrey, S.C. et al. (May-Jun. 2006, e-pub. May 3, 2006). “Development and Properties of Beta-Glucuronide Linkers for Monoclonal Antibody-Drug Conjugates,” American Chemical Society 17(3):A-J.
[cited by applicant]
Jones, P.T. et al. (May 29, 1986). “Replacing the Complementarity-Determining Regions in a Human Antibody With Those From a Mouse,” Nature 321:522-525.
[cited by applicant]
Kabat, E.A. et al. (Sep. 1980). “Origins of Antibody Complementarity and Specificity-Hypervariable Regions and the Minigene Hypothesis,” J Immunology 125(3):961-969.
[cited by applicant]
Kaneko, T. et al. (May-Jun. 1991). “New Hydrazone Derivatives of Adriamycin and Their Immunoconjugates—A Correlation Between Acid Stability and Cytotoxicity,” Bioconjugate Chem. 2(3):133-141.
[cited by applicant]
Kozbor, D. et al. (1983). “The Production of Monoclonal Antibodies From Human Lymphocytes,” Immunology Today 4(3):72-79.
[cited by applicant]
Laguzza, B.C. et al. (Mar. 1989). “New Antitumor Monoclonal Antibody-Vinca Conjugates LY203725 and Related Compounds: Design, Preparation, and Respresentative in Vivo Activity,” J. Med. Chem. 32(3):548-555.
[cited by applicant]
Lau, U.Y. et al. (Aug. 1, 2018). “Lactone Stabilization is Not a Necessary Feature for Antibody Conjugates of Camptothecins,” Molecular Pharmaceutics 15(9):4063-4072.
[cited by applicant]
Li, W. et al. (Sep. 6, 2019). “Synthesis and Evaluation of Camptothecin Antibody-Drug Conjugates,” ACS Medicinal Chemistry Letters 10(10):1386-1392.
[cited by applicant]
Liu, A.Y. et al. (May 1987). “Chimeric Mouse-Human IgG1 Antibody That Can Mediate Lysis of Cancer Cells,” Proc. Natl. Acad. Sci. USA 84:3439-3443.
[cited by applicant]
Liu, A.Y. et al. (Nov. 15, 1987). “Production of a Mouse-Human Chimeric Monoclonal Antibody to CD20 With Potent Fc-Dependent Biologic Activity,” J. Immunol. 139(10):3521-3526.
[cited by applicant]
Lyon, R.P. et al. (Oct. 2014, e-pub. Sep. 7, 2014). “Self-hydrolyzing Maleimides Improve the Stability and Pharmacological Properties of Antibody-Drug Conjugates,” Nat Biotechnol 32(10): 1059-1062.
[cited by applicant]
Malik, F. et al. (Sep. 1992). “Polyethylene glycol (PEG)-Modified Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Conserved Biological Activity,” Exp. Hematol. 20(8):1028-1035.
[cited by applicant]
Morrison, S.L. (Sep. 1985). “Transfectomas Provide Novel Chimeric Antibodies,” Science 229(4719):1202-1207.
[cited by applicant]
Nishimura, Y. et al. (Feb. 15, 1987). “Recombinant Human-Mouse Chimeric Monoclonal Antibody Specific for Common Acute Lymphocytic Leukemia Antigen,” Cancer. Res. 47(4):999-1005.
[cited by applicant]
Non-Final Office Action, mailed Feb. 4, 2021, for U.S. Appl. No. 16/376,302, filed Apr. 5, 2019, 18 pages.
[cited by applicant]
Oi, V.T. et al. (1986). “Chimeric Antibodies,” Bio Techniques 4(3):214-219.
[cited by applicant]
Olsson, L. et al. (1983), “Human-Human Monoclonal Antibody-Producing Hybridomas: Technical Aspects,” Meth Enzymol. 92:3-16.
[cited by applicant]
Reider, P.J. et al. (Jul. 1, 1987). “Synthesis of (R)-Serine-2-d and Its Conversion to the Broad-Spectrum Antibiotic Fludalanine,” J. Org. Chem. 52:3326-3334.
[cited by applicant]
Rodrigues, M.L. et al. (Apr. 1995). “Synthesis and β-Lactamase-Mediated Activation of a Cephalosporine-Taxol Prodrug,” Chem. Biol. 2:223-227.
[cited by applicant]
Rose, K. et al. (May-Jun. 1991). “Preparation of Well-Defined Protein Conjugates Using Enzyme-Assisted Reverse Proteolysis,” Bioconjugate Chem. 2(3):154-159.
[cited by applicant]
Schmidt, M.M. et al. (Oct. 2009). “A Modeling Analysis of the Effects of Molecular Size and Binding Affinity on Tumor Targeting,” Mol. Cancer Ther. 8(10):2861-2871.
[cited by applicant]
Schwartz, A. et al. (1990). “Enzymatic C-Terminal Biotinylation of Proteins,” Methods Enzymol. 184:160-162.
[cited by applicant]
Shaw, D.R. et al. (Dec. 7, 1988). “Mouse/Human Chimeric Antibodies to a Tumor-Associated Antigen: Biologic Activity of the Four Human IgG Subclasses,” J. Natl. Cancer Inst. 80(19):1553-1559.
[cited by applicant]
Storm, D.R. et al. (Aug. 9, 1972). “Effect of Small Changes in Orientation on Reaction Rate,” Journal of the American Chemical Society 94(16):5815-5825.
[cited by applicant]
Sun, L.K. et al. (Jan. 1987). “Chimeric Antibody With Human Constant Regions and Mouse Variable Regions Directed Against Carcinoma-Associated Antigen 17-1A,” Proc. Natl. Acad. Sci. USA 84(1):214-218.
[cited by applicant]
Teng, N.N.H. et al. (Dec. 1983). “Construction and Testing of Mouse-Human Heteromyelomas for Human Monoclonal Antibody Production,” Proc. Natl. Acad. Sci. USA. 80:7308-7312.
[cited by applicant]
Toki, B.E. et al. (2002, e-pub. Feb. 12, 2002). “Protease-Mediated Fragmentation of p-Amidobenzyl Ethers: A New Strategy for the Activation of Anticancer Prodrugs,” J. Org. Chem. 67(6):1866-1872.
[cited by applicant]
U.S. Appl. No. 16/972,469, filed Dec. 4, 2020, Jeffrey et al. (Copy not submitted herewith pursuant to the waiver of 37 C.F.R. § 1.98(a)(2)(iii) issued by the Office on Sep. 21, 2004).
[cited by applicant]
Verhoeyan, M. et al. (Mar. 25, 1988). “Reshaping Human Antibodies: Grafting an Antilysozyme Activity,” Science 239:1534-1536.
[cited by applicant]
Veronese, F.M. (2001). “Peptide and Protein PEGylation: A Review of Problems and Solutions,” Biomaterials 22:405-417.
[cited by applicant]
Veronese, F.M. et al. (Apr. 1985). “Surface Modification of Proteins: Activation of Monomethoxy-Polyethylene Glycols by Phenylchloroformates and Modification of Ribonuclease and Superoxide Dismutase,” Appl. Biochem. Bio…
[cited by applicant]
Wadkins, R.M. et al. (Sep. 15, 2004). “Hydrophilic Camptothecin Analogs That Form Extremely Stable Cleavable Complexes With DNA and Topoisomerase I,” Canc. Res. 64:6679-6683.
[cited by applicant]
Walker, M.A. et al. (Jan. 21, 2002). “Synthesis of an Immunoconjugate of Camptothecin,” Bioorganic & Medicinal Chemistry Letters 12(2):217-219.
[cited by applicant]
Wood, C.R. et al. (Apr. 4, 1985). “The Synthesis and in vivo Assembly of Functional Antibodies In Yeast,” Nature 314(6010):446-449.
[cited by applicant]
Xie, Z.-F. et al. (1995). “Convergent Approach to Water Soluble Camptothecin Derivatives,” Bioorganic & Medicinal chemistry Letters 5(19):2189-2194.
[cited by applicant]
Yao, H. et al. (Feb. 2, 2016). “Methods to Design and Synthesize Antibody Drug Conjugates (ADCs),” Int. J. Mol. Sci. 17(194):1-16.
[cited by applicant]
Abdiche, Y. N. et al. (Aug. 31, 2012, e-pub. May 17, 2012). “Label-Free Epitope Binning Assays of Monoclonal Antibodies Enable the Identification of Antigen Heterogeneity,” Journal of Immunological Methods 382(1-2):101-…
[cited by applicant]
Abdiche, Y. N. et al. (Mar. 20, 2014). “High-throughput Epitope Binning Assays on Label-free Array-based Biosensors can Yield Exquisite Epitope Discrimination that Facilitates the Selection of Monoclonal Antibodies with…
[cited by applicant]
Abdiche, Y.N. et al. (Mar. 15, 2009, e-pub. Dec. 7, 2008). “Exploring Blocking Assays Using Octet, ProteOn, and Biacore Biosensors,” Analytical Biochem 386(2):172-180.
[cited by applicant]
Abuelgasim, K.A. et al. (2019, e-pub. Jan. 30, 2019). “Chemoimmunotherapy With Brentuximab Vedotin Combine With Ifosfamide, Gemcitabine, and Vinorelbine is Highly Active in Relapsed or Refractory Classical Hodgkin Lymph…
[cited by applicant]
Adams, D.J. et al. (2006, e-pub. Aug. 20, 2005). “Camptothecin Analogs with Enhanced Activity Against Human Breast Cancer Cells. I. Correlation of Potency with Lipophilicity and Persistence in the cleavage Complex,” Can…
[cited by applicant]
Akewanlop, C. et al. (May 15, 2001). “Phagocytosis of Breast Cancer Cells Mediated by Anti-MUC-1 Monoclonal Antibody, DF3, and Its Bispecific Antibody,” Cancer Res. 61:4061-4065.
[cited by applicant]
Al-Lazikani, B. et al. (1997). “Standard Conformations for the Canonical Structures of Immunoglobulins,” J. Mol. Biol. 273:927-948.
[cited by applicant]
Almagro, J.C. et al. (Jan. 1, 2008). “Humanization of Antibodies,” Front. Biosci. 13:1619-1633.
[cited by applicant]
Anonymous (Oct. 2, 2020). “The Fiery ADC, the Ever-Changing Three Musketeers,” from the Internet https://www.pharmcube.com/index/news/article/5630, last visited Oct. 2, 2020, 9 pages.
[cited by applicant]
Arimondo, P.B. et al. (Feb. 1, 2002). “Design and Optimization of Camptothecin Conjugates of Tripled Helix-Forming Oligonucleotides for Sequence-Specific DNA Cleavage by Topoisomerase I,” J. Biol. Chem. 277(5):3132-3140.
[cited by applicant]
Ashkenazi, A. et al. (Dec. 1991). “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin,” Proc. Natl. Acad. Sci. USA 88:10535-10539.
[cited by applicant]
Asseman, C. et al. (Oct. 4, 1999). “An Essential Role for Interleukin 10 in the Function of Regulatory T Cells That Inhibit Intestinal Inflammation,” J. Exp. Med. 190(7):995-1003.
[cited by applicant]
ATCC CCL 10 (No Date). “BHK-21 (C-13); Kidney; Syrian golden hamster (
[cited by applicant]
ATCC CCL 2 (No Date). “HeLa; Cervical Adenocarcinoma; Human (
[cited by applicant]
ATCC CCL 34 (No Date). “MDCK (NBL-2); Kidney; Dog (
[cited by applicant]
ATCC CCL 51 (No Date). “MMT 060562,” 7 pages.
[cited by applicant]
ATCC CCL 61 (No Date). “CHO-K1 Ovary Chinese Hamster (
[cited by applicant]
ATCC CCL 70 (No Date). “CV-1; Kidney; African Green Monkey (
[cited by applicant]
ATCC CCL 75 (No Date). “WI-38; Lung Fibroblast; Human (
[cited by applicant]
ATCC CCL 1442 (No Date). “BRL 3A; Liver; Rat (
[cited by applicant]
ATCC CCL 1651 (No Date). “COS-7; Kidney Fibroblast; African Green Monkey (
[cited by applicant]
ATCC CRL-1587 (No Date). “Vero 76; Kidney; African Green Monkey (
[cited by applicant]
Ausubel, F. et al. (1987). Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York, TOC, 7 pages.
[cited by applicant]
Baca, M. et al. (Apr. 18, 1997). “Antibody Humanization Using Monovalent Phage Display,” J. Biol. Chem. 272(16):10678-10684.
[cited by applicant]
Barth, S. et al. (Jun. 15, 2000). “Ki-4(scFv)-ETA, a New Recombinant anti-CD30 Immunotoxin With Highly Specific Cytotoxic Activity Against Disseminated Hodgkin Tumors in SCID Mice,” Blood 95(12):3909-3914.
[cited by applicant]
Baudat, Y. et al. (Apr. 14-19, 2023). “A Novel Topoisomerase I Inhibitor Antibody-Drug Conjugate Targeting CEACAM5 has Potent Anti-Tumor activity in Colorectal Cancer Models,” AACR, Poster # 4890, 1 page.
[cited by applicant]
Belkaid, Y. (Nov. 2007, e-pub. Oct. 19, 2007). “Regulatory T Cells and Infection: A Dangerous Necessity,” Nature Reviews 7:875-888.
[cited by applicant]
Benoist, C. et al. (Mar. 26, 1981). “In Vivo Sequence Requirements of the SV40 Early Promotor Region,” Nature 290:304-310.
[cited by applicant]
Bettini, M. et al. (Dec. 2009, e-pub. Dec. 1, 2010). “Regulatory T Cells and Inhibitory Cytokines in Autoimmunity,” Curr. Opin. Immunol. 21(6):612-618, 12 pages.
[cited by applicant]
Bird, R.E. et al. (Oct. 21, 1988). “Single-Chain Antigen-Binding Proteins,” Science 242(4877):423-426.
[cited by applicant]
Bowen, M.A. et al. (Dec. 1, 1993). “Functional Effects of CD30 on a Large Granular Lymphoma Cell Line, YT. Inhibition of Cytotoxicity, Regulation of CD28 and IL-2R, and Induction of Homotypic Aggregation,” J. Immunol. 1…
[cited by applicant]
Brennan, M. et al. (Jul. 5, 1985). “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments,” Science 229:81-83.
[cited by applicant]
Bricogne, G. (1997). “Bayesian Statistical Viewpoint on Structure Determination: Basic Concepts and Examples,” Meth Enzymol 276:361-423.
[cited by applicant]
Bricogne, G. (Jan. 1, 1993). “Direct Phase Determination by Entropy Maximization and Likelihood Ranking: Status Report and Perspectives,” Acta Crystallogr D Biol Crystallogr D49(Pt 1):37-60.
[cited by applicant]
Brinster, R.L. et al. (Mar. 4, 1982). “Regulation of Metallothionein-Thymidine Kinase Fusion Plasmids Injected Into Mouse Eggs,” Nature 296:39-42.
[cited by applicant]
Byrn, R.A. et al. (Apr. 12, 1990). “Biological Properties of a CD4 Immunoadhersin,” Nature 344(6267):667-670.
[cited by applicant]
Capel, P.J.A. et al. (Feb. 1994). “Heterogeneity of Human IgG Fc Receptors,” Immunomethods 4(1):25-34.
[cited by applicant]
Cardillo, T.M. et al. (2011). “Humanized Anti-Trop-2 IgG-SN-38 Conjugate for Effective Treatment of Diverse Epithelial Cancers: Preclinical Studies in Human Cancer Xenograft Models and Monkeys,” Clinical Cancer Research…
[cited by applicant]
Carter, P. et al. (May 1992). “Humanization of an Anti-p185HER2 Antibody for Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA 89:4285-4289.
[cited by applicant]
CAS RN149882-14-4 to RN1596548-57-0, 2 pages.
[cited by applicant]
CAS RN1596548-57-0 to RN160469-20-5, 19 pages.
[cited by applicant]
CAS: 55750-62-4 (No Date). “3-Maleimidopropionic Acid N-Succinimidyl Ester (CAS 55750-62-4),” 3 pages.
[cited by applicant]
CAS: 955094-26-5 (No Date). “Maleimide-PEG2-NHS (CAS 955094-26-5),” 2 pages.
[cited by applicant]
CAS:1174157-65-3 (No Date). “Propargyl-succinimidyl-ester (CAS 1174157-65-3),” 2 pages.
[cited by applicant]
Chang, B.S. et al. (Feb. 1996). “Development of a Stable Freeze-Dried Formulation of Recombinant Human Interleukin-1 Receptor Antagonist,” Pharm. Res. 13(2):243-249.
[cited by applicant]
Charoentong, P. et al. (Jan. 3, 2017). “Pan-Cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade,” Cell Reports 18:248-262.
[cited by applicant]
Chayen, N.E. (Oct. 15, 1997). The Role of Oil in Macromolecular Crystallization, Structure 5(10):1269-1274.
[cited by applicant]
Cheson, B.D. et al. (Sep. 20, 2014). “Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification,” J Clin Oncol 32(27):3059-3068.
[cited by applicant]
Chothia, C. et al. (Aug. 20, 1987). “Canonical Structures for the Hypervariable Regions of Immunoglobulins,” J. Mol. Biol. 196(4):901-917.
[cited by applicant]
Chowdhury, P.S. (Mar. 2008. “Engineering Hot Spots for Affinity Enhancement of Antibodies,” Methods Mol. Biol. 207:179-196.
[cited by applicant]
Chu, G. et al. (Mar. 1981). “SV40 DNA Transfection of Cells in Suspension: Analysis of the Efficiency of Transcription and Translation of T-Antigen,” Gene 13(2):197-202.
[cited by applicant]
Clynes, R. et al. (Jan. 1998). “Fc Receptors are Required in Passive and Active Immunity to Melanoma,” Proc. Natl. Acad. Sci. USA 95:652-656.
[cited by applicant]
Coligan, J.E. et al. (1991). Current Protocols in Immunology 3.12-3.12.14.
[cited by applicant]
Collison, L.W. et al. (2009). “Regulatory T Cell Suppression Is Potentiated by Target T Cells in a Cell Contact, IL-35- and IL-10-Dependent Manner,” J. Immunol. 182:6121-6128.
[cited by applicant]
Collison, L.W. et al. (2011, e-pub. Jan. 1, 2012). “In Vitro Treg Suppression Assays,” Methods Molecular Biology 707:21-37, 18 pages.
[cited by applicant]
Cromie, K.D. et al. (2015). “Nanobodies and Their Use in GPCR Drug Discovery,” Curr. Top. Med. Chem. 15(24):2543-2557.
[cited by applicant]
Cunningham, B.C. et al. (Jun. 2, 1989). “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,” Science 244:1081-1085.
[cited by applicant]
Dall'Acqua, W.F. et al. (2005). “Antibody Humanization by Framework Shuffling,” Methods 36:43-60.
[cited by applicant]
Dannull, J. et al. (Dec. 2005). “Enhancement of Vaccine-Mediated Antitumor Immunity in Cancer Patients After Depletion of Regulatory T Cells,” J Clin Invest 115(12):3623-3633.
[cited by applicant]
Davies, J. et al. (Aug. 20, 2001). “Expression of GnTIII in a Recombinant Anti-CD20 CHO Production Cell Line: Expression of Antibodies With Altered Glycoforms Leads to an Increase in ADCC Through Higher Affinity for FC …
[cited by applicant]
Daeron, M. (1997). “Fc Receptor Biology,” Ann. Rev. Immunol. 15:203-234.
[cited by applicant]
De Haas, M. et al. (1995). Fcγ Receptors of Phagocytes, J. Lab. Clin. Med. 126(4):330-341.
[cited by applicant]
De Meyer, T. et al. (May 2014). “Nanobody-Based Products as Research and Diagnostic Tools,” Trends Biotechnol. 32(5):263-270.
[cited by applicant]
De Pascalis, R. et al. (2002). “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential For Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal …
[cited by applicant]
Deboer, H.A. et al. (Jan. 1983). “The Tac Promoter: a Functional Hybrid Derived From the trp and lac Promoters,” Proc. Natl. Acad. Sci. U.S.A. 80(1):21-25.
[cited by applicant]
Degenst, E. et al. (2006, e-pub. Jul. 11, 2005). “Antibody Repertoire Development in Camelids,” Dev. Comp. Immunol. 30:187-198.
[cited by applicant]
Del Poeta, M. et al. (Dec. 1999). “Comparison of in vitro Activities of Camptothecin and Nitidine Derivatives Against Fungal and Cancer Cells,” Antimicrobial Agents and Chemotherapy 43(12):2862-2868.
[cited by applicant]
Dieckmann, D. et al. (Jun. 4, 2001). “Ex Vivo Isolation and Characterization of CD4+ CD25+ T Cells with Regulatory Properties from Human Blood,” J. Exp. Med. 193(11):1303-1310.
[cited by applicant]
Dotan, E. et al. (Oct. 10, 2017). “Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients with Refractory or Relapsing Metastatic Colorectal Cancer,” Journal of Clinical Oncol…
[cited by applicant]
Dürkop, H. et al. (Feb. 7, 1992). “Molecular Cloning and Expression of a New Member of the Nerve Growth Factor Receptor Family That is Characteristic for Hodgkin's Disease,” Cell 68:421-427.
[cited by applicant]
Eisenhauer, E.A. et al. (2009) “New Response Evaluation Criteria in Solid Tumors: Revised Recist Guideline (version 1.1),” Eur. J. Cancer 45:228-247.
[cited by applicant]
Endo, Y. et al. (2003). “High-Throughput, Genome-Scale Protein Production Method Based on the Wheat Germ Cell-Free Expression System,” Biotechnol. Adv. 21:695-713.
[cited by applicant]
Engert, A. et al. (Jan. 1, 1990). “Evaluation of Ricin A Chain-Containing Immunotoxins Directed Against the CD30 Antigen as Potential Reagents for the Treatment of Hodgkin's Disease,” Cancer Research 50:84-88.
[cited by applicant]
Epstein, D. (Jan. 9, 2023). “Building Oncology Leadership: Novel ADCs & Targeted Therapies,” J.P. Morgan Healthcare Conference, 26 pages.
[cited by applicant]
Extended European Search Report, dated Jun. 5, 2023, for European Patent Application No. 22306780.2, 9 pages.
[cited by applicant]
Falini, B. et al. (May 16, 1992). “Responses of Refractory Hodgkin's Disease to Monoclonal Anti-CD30 Immunotoxin,” The Lancet 339:1195-1196.
[cited by applicant]
Falini, B. et al. (Sep. 1992). “In vivo Targeting of Hodgkin and Reed-Sternberg Cells of Hodgkin's Disease With Monoclonal Antibody Ber-H2 (CD30): Immunohistological Evidence,” British Journal of Haematology 82(1):38-45.
[cited by applicant]
Fanslow, W.C. et al. (1994). “Structural Characteristics of CD40 Ligand that Determine Biological Function,” Semin. Immunol. 6:267-278.
[cited by applicant]
Ferguson, W.J. et al. (May 15, 1980). “Hydrogen Ion Buffers for Biological Research,” Anal. Biochem. 104(2):300-310.
[cited by applicant]
Foote, J. et al. (1992). “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops,” J Mol Biol. 224(2): 487-499.
[cited by applicant]
Francisco, J.A. et al. (Aug. 15, 2003, e-pub. May 8, 2003). “cAC10-vcMMAE, an Anti-CD30-Monomethyl Auristatin E Conjugate With Potent and Selective Antitumor Activity,” Blood 102(4):1458-1465.
[cited by applicant]
Freshney, R. I. (1987). “Culture of Specific Cell Types,” Chapter 20 in Culture of Animal Cells: A Manual of Basic Techniques, Alan R. Liss & Co., New York; pp. 257-260, 270-273.
[cited by applicant]
Fridman, W.H. et al. (Mar. 2012, e-pub. Apr. 2012). “The Immune Contexture in Human Tumours: Impact on Clinical Outcome,” Nature Reviews Cancer 12:298-306.
[cited by applicant]
Froese, P. et al. (Sep. 15, 1987). “Biochemical Characterization and Biosynthesis of the Ki-1 Antigen in Hodgkin-derived and Virus-Transformed Human B and T Lymphoid Cell Lines,” J. Immunol. 139(6):2081-2087.
[cited by applicant]
Gazzano-Santoro, H. et al. (1997). “A Non-Radioactive Complement-Dependent Cytotoxicity Assay for Anti-CD20 Monoclonal Antibody,” J. Immunol. Methods 202:163-171.
[cited by applicant]
GenBank AAA51967.1 (Nov. 1, 1994). “Carcinoembryonic Antigen [Homo sapiens],” 5 pages.
[cited by applicant]
Ghetie, V. et al. (2000). “Multiple Roles for the Major Histocompatibility Complex Class I-Related Receptor FCRN,” Annu. Rev.Immunol. 18:739-766, 32 pages.
[cited by applicant]
Ghetie, V. et al. (2002). “Transcytosis and Catabolismof Antibody,” Immunol. Res. 25(2):97-113.
[cited by applicant]
Ghetie, V. et al. (Dec. 1997). “FcRn: the MHC Class I-Related Receptor That Is More Than an IgG Transporter,” Immunol. Today 18(12):592-598, 7 pages.
[cited by applicant]
Ghetie, V. et al. (Jul. 1997). “Increasing the Serum Persistence of an IgG Fragment by Random Mutagenesis,” Nat Biotech 15:637-640.
[cited by applicant]
Giegé, R. et al. (Jul. 1, 1994). Crystallogenesis of Biological Macromolecules: Facts and Perspectives, Acta Crystallogr D Biol Crystallogr D50(Pt 4):339-350.
[cited by applicant]
Gold, P. et al. (1965). “Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by Immunological Tolerance and Absorption Techniques.” Freedman, J Exp Med, 121:439-462, 33 pages.
[cited by applicant]
Good, N.E. et al. (1972). “Hydrogen lon Buffers,” Methods Enzymol. 24:53-68.
[cited by applicant]
Good, N.E. et al. (Feb. 1966). “Hydrogen Ion Buffers for Biological Research,” Biochemistry 5(2):467-477.
[cited by applicant]
Govindan, S.V. et al. (Oct. 1, 2009). “CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates,” Clinical Cancer Research 15(19):6052-6061.
[cited by applicant]
Graham, F.L. et al. (1977). “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen Virol. 36:59-72.
[cited by applicant]
Graham, F.L. et al. (Apr. 1973). “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,” Virology 52(2):456-467.
[cited by applicant]
Gruber, M. et al. (1994). “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in
[cited by applicant]
Guyer, R.L. et al. (Aug. 1976). “Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors,” J. Immunol. 117(2):587-593.
[cited by applicant]
Hambly, D.M. et al. (2005). “Laser Flash Photolysis of Hydrogen Peroxide to Oxidize Protein Solvent-Accessible Residues on the Microsecond Timescale,” J. American Soc. Mass Spectrometry 16:2057-2063.
[cited by applicant]
Herrera, A.F. et al. (Mar. 15, 2018, e-pub. Dec. 11, 2017). “Interim Results of Brentuximab Vedotin in Combination with Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma,” Blood 131(11):1183-1194.
[cited by applicant]
Hinton, P.R. et al. (Feb. 20, 2004). “Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates,” J. Biol. Chem. 279(8):6213-6216.
[cited by applicant]
Hollenbaugh, D. et al. (May 2002). “Construction of Immunoglobulin Fusion Proteins,” in Current Protocols in Immunology Chapter 10:unit 10.19.1-10.19.11, 11 pages.
[cited by applicant]
Hollinger, P. et al. (Jul. 1993). “Diabodies: Small Bivalent and Bispecific Antibody Fragments,” Proc. Natl. Acad. Sci. USA 90:6444-6448.
[cited by applicant]
Honegger, A. et al. (Jun. 8, 2001). “Yet Another Numbering Scheme for Immunoglobulin Variable Domains: An Automatic Modeling and Analysis Tool,” J. Mol. Biol. 309:657-670.
[cited by applicant]
Hoogenboom, H.R. et al. (2001) “Overview of Antibody Phage-Display Technology and Its Applications,” Methods in Molecular Biology 178:1-37.
[cited by applicant]
Hoppe, H.-J. et al. (1994). “A Parallel Three Stranded Alpha-Helical Bundle at the Nucleation Site of Collagen Triple-Helix Formation,” FEBS Lett. 344:191-195.
[cited by applicant]
Huston, J.S et al. (Aug. 1988). “Protein Engineering of Antibody Binding Sites: Recovery of Specific Activity in an Anti-Digoxin Single-chain Fv Analogue Produced in
[cited by applicant]
Idusogie, E.E. et al. (2000). “Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody With a Human IgG1 Fc,” J. Immunol. 164:4178-4184.
[cited by applicant]
Idusogie, E.E. et al. (2001). “Engineered Antibodies With Increased Activity to Recruit Complement,” J. Immunol. 166:2571-2575.
[cited by applicant]
International Search Report and Written Opinion, mailed Mar. 15, 2024, for PCT Application No. PCT/US2023/080162, filed Nov. 16, 2023, 16 pages.
[cited by applicant]
Iwahashi, M. et al. (Oct.-Nov. 1999). “CDR Substitutions of a Humanized Monoclonal Antibody (CC49): Contributions of Individual CDRs to Antigen Binding and Immunogenicity,” Mol. Immunol. 36(15-16):1079-1091.
[cited by applicant]
Japanese Notice, dated Mar. 25, 2024, for Japanese Patent Application 2020-567763, 1 page.
[cited by applicant]
Japanese Third-Party Observation, dated Mar. 25, 2024, for Japanese Patent Application 2020-567763, 9 pages.
[cited by applicant]
Josimovic-Alasevic, O. et al. (Janaury 1989). “Ki-1 (CD30) Antigen Is Released by Ki-1-positive Tumor Cells in vitro and in vivo. I. Partial Characterization of Soluble Ki-1 Antigen and Detection of the Antigen in Cell …
[cited by applicant]